Redacción MSD presenta resultados positivos de un anticuerpo en investigación para virus respiratorio sincitial Merck Sharp & ...

La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK ... línea para las mujeres adultas con cáncer de endometrio avanzado, tanto de nuevo diagnóstico como en recaída.

La Comisión Europea ha aprobado JEMPERLI (dostarlimab), de GSK, en combinación con quimioterapia estándar (carboplatino y paclitaxel) como tratamiento de primera línea para todas las pacientes adultas ...

Así nos lo confirma la doctora Ana Conde, especialista del Servicio de Ginecología Oncológica de MD Anderson Cancer Center Madrid-Hospiten, quien nos explica que el de endometrio es el tumor ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck & Co crashed the party.

A ketogenic diet may have health benefits for the treatment or prevention of cancer. But research is mixed, and it can have downsides for people receiving ongoing cancer treatment. Cancer is most ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...